The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2022 | Safety and efficacy of cesnicabtagene autoleucel (ARI0002h) for R/R MM
Carlos Fernández De Larrea
• 10 Jun 2022
Carlos Fernandez de Larrea, MD, PhD, University of Barcelona, Barcelona, Spain, discusses the safety and efficacy of cesnicabtagene autoleucel (ARI0002h), a novel academic BCMA-directed CAR-T therapy, for the treatment of patients with relapsed/refractory (R/R) multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
